EUVIMED · CrossrefZeitschrift
Onkologie
ISSN 0378-584X · S. Karger AG
Neueste Artikel
Bone Marrow Metastases in a Patient with Primary Mediastinal Non-Seminomatous Germ Cell Tumor – an Unusual Pattern of Relapse
Malignant Perivascular Epithelioid Cell Tumor of the Mesentery: A Case Report and Literature Review
Effects of a Physical Exercise Rehabilitation Group Program on Anxiety, Depression, Body Image, and Health-Related Quality of Life among Breast Cancer Patients
Quality Assured Health Care in Certified Breast Centers and Improvement of the Prognosis of Breast Cancer Patients
Etiology of Melanoma
Die Klinik des multiplen Myeloms
Metastatic Melanoma: Scientific Rationale for Sorafenib Treatment and Clinical Results
Erratum zu Onkologie 2000;23:603–613
1. Phase I and Phase II Study Groups
2. Phase III Study Group
3. New Drug Development Group (AWO)
4. Study Group of Pharmacology in Oncology and Hematology (APOH)
5. EORTC New Drug Development and Coordinating Committee (EORTCNDDCC)
Fortschritte in der Diagnostik und Therapie des Blasenkarzinoms
Vol. 23, Supplement 3, April 2000
Status of Topotecan in Small-Cell Lung Cancer
Phase I and Phase II Evaluation of Novel Anticancer Agents: Are Response and Toxicity the Right Endpoints?
Topotecan/Taxol in First-Line Small-Cell Lung Cancer: Where Is the Benefit?
Topotecan in Second-Line Therapy of SCLC: Impact on Survival?
Topotecan in the First-Line Treatment of Small-Cell Lung Cancer
Concluding Remarks
Gemeinsame Jahrestagung
Band 25, Supplement 3, August 2002
Einleitung
Abstracts
Erratum
Zielgerichtete Tumortherapie
Vorwort: «Targeted therapy in oncology» – von der Forschung zur klinischen Praxis
Aktive Immuntherapie bei Patienten mit hämatologischen und soliden Neoplasien
Passive Immuntherapie mit monoklonalen Antikörpern
EUVIMED